Paper Details

  1. Home
  2. Paper Details

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient.

Author: BigirimanaFerdinand, ClevenberghPhilippe, FossoChristelle, MaillartEvelyne, MartinCharlotte, StoffelsKarolien, Van den WijngaertSigi

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

A patient with end-stage renal disease and multidrug-resistant (MDR) HIV infection successfully maintained viral suppression for over a year after switching to a combination of fostemsavir and lenacapavir plus lamivudine. This combination shows promise for treating MDR HIV in patients with renal impairment.
Paper Details　
Original Abstract of the Article :
We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir loo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599868/

データ提供：米国国立医学図書館（NLM）

Lenacapavir and Fostemsavir: A New Combination for Multidrug-Resistant HIV

Managing multidrug-resistant HIV (MDR HIV) is a significant challenge for healthcare providers. This study reports a case of a patient with MDR HIV who was successfully treated with a combination of [lenacapavir] and [fostemsavir], two new antiretroviral drugs. The patient, who was also undergoing [hemodialysis], showed a suppressed viral load and experienced no significant side effects. This case report highlights the potential of this new drug combination for treating MDR HIV, particularly in patients with [end-stage renal disease (ESRD)].

New Hope for MDR HIV: Lenacapavir and Fostemsavir Show Promise

The study's findings suggest that the combination of lenacapavir and fostemsavir could be a valuable tool for managing MDR HIV, offering an effective treatment option for patients who have developed resistance to other antiretroviral therapies.

A New Era in HIV Treatment: Harnessing Innovation for Better Outcomes

This research underscores the importance of ongoing research and development in the field of HIV treatment. The emergence of new drugs like lenacapavir and fostemsavir offers hope for individuals with MDR HIV, paving the way for more effective and tolerable treatment options.

Dr.Camel's Conclusion

Just like camels have adapted to survive in harsh desert environments, individuals with MDR HIV are facing their own set of challenges. This study provides a ray of hope, demonstrating the potential of new drug combinations for effectively managing this complex condition and improving the lives of those affected.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-10-28
Further Info :

Pubmed ID

37886135

DOI: Digital Object Identifier

PMC10599868

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.